Sep 2026
Abstract B053: RAS(ON) inhibition, but not chemotherapy, sensitizes RAS mutant PDAC to immunotherapy via tumor microenvironment remodeling in preclinical models
Pancreatic ductal adenocarcinoma (PDAC) remains largely refractory to immune checkpoint blockade and combining anti-PD-(L)1 therapy with standard-of-care chemotherapy has not improved clinical outcomes over chemotherapy alone. Because oncogenic RAS drives both tumor growth and tumor-intrinsic immune suppression, we h...
L. Grigoryan, Keith Macaraig, Victor Batiste et al.
· Cancer Research · 0 citations